Stockpolly
Search
OSTX · AMEX · Biotechnology

OS Therapies (OSTX)

Develops Listeria immunotherapy for recurrent metastatic osteosarcoma after surgery.

$1.75
Pre-market+0.04 (+2.04%)
At close$1.72(+3.31%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue00000000000
Gross profit00000000000
1112355712108
Research & development1001112416,35376,074
0001242312,33632,501
General & administrative0001042312,34332,501
Other expenses00000000−28,6770−8,567
Operating income−1−1−1−2−3−5−5−7−12−10−9
0−1−100100−100
Interest income00000000000
Interest expense01100000000
Other non-operating income00000−100100
Income before tax−1−1−2−3−3−4−5−7−13−10−9
Net income from continuing operations−1−1−2−3−3−4−5−7−13−10−9
Net income−1−1−2−3−3−4−5−7−13−10−9
EPS, basic−$0.07−$0.07−$0.08−$0.18−$0.04−$0.18−$0.18−$0.21−$0.41−$0.27−$0.20
EPS, diluted−$0.07−$0.07−$0.08−$0.18−$0.04−$0.18−$0.18−$0.21−$0.41−$0.27−$0.20
Weighted average shares, basic20202116124212532293944
Weighted average shares, diluted20202116124212532293944
EBITDA−1−1−1−2−3−4−4−7−13−10−8
Depreciation & amortization00000000000
EBIT−1−1−1−2−3−4−5−7−13−10−9